EichenfieldLF, StriplingS, FungS, et al.Recent developments and advances in atopic dermatitis: A focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Paediatr Drugs. 2022; 24(4):293–305.
2.
NapolitanoM, FabbrociniG, MartoraF, et al.Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022; 35(12):e15901.
3.
FrazierW, BhardwajN. Atopic dermatitis: Diagnosis and treatment. Am Fam Physician. 2020; 101(10):590–598.
PotestioL, PatrunoC, DastoliS, et al.Tralokinumab for the treatment of adult atopic dermatitis in special populations. J Asthma Allergy. 2024; 17:791–799.
6.
PezzoloE, SechiA, TartagliaJ, et al.A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults. Expert Rev Clin Immunol. 2024; 20(3):255–266.
7.
GargiuloL, IbbaL, VignoliCA, et al.Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: A real-life 16-week experience. J Dermatolog Treat. 2023; 34(1):2216815.
8.
PotestioL, PatrunoC, NapolitanoM. Efficacy and safety of tralokinumab in real life: Possible predictive rapid response factors. Dermatitis. 2024; 35(S1):S77–S80.
9.
Pereyra-RodríguezJJ, HerranzP, Ruiz-VillaverdeR, et al.Treatment of severe atopic dermatitis with tralokinumab in clinical practice: Short-term effectiveness and safety results. Clin Exp Dermatol. 2023; 48(9):991–997.
10.
MerolaJF, ButlerDC, MarkT, et al.Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: A secondary analysis. JAMA Dermatol. 2023; 159(10):1119–1123.
